British pharmaceutical company AstraZeneca has asked the US Food and Drug Administration for an emergency authorization for a new antibody drug that reduces the risk of developing COVID symptoms by 77%. Reported by The Guardian. The new drug is an antibody therapy called AZD7442. It contains laboratory antibodies designed to remain in the body for months to contain the virus in the event of an infection. AstraZeneca says it can help protect people who may not have a strong enough immune response to COVID vaccines. As previously reported, Pfizer and Moderna booster doses were recommended in the EU. The effectiveness of Pfizer's COVID vaccine halves in half a year - Scientists News from Telegram. Subscribe to our channel https: // t. me / korrespondentnet Author: 1.